Assessment of Real-World Treatment Patterns and Outcomes in Relapsed or Refractory Multiple Myeloma: Evidence From a Brief Multicountry Survey of European Physicians Keith L Davis, Huamao Mark Lin, Ai-Min Hui, Shumin Zhang, James A Kaye RTI Health Solutions, Research Triangle Park, NC, United States; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Li...

"Endocrine disruption" is a public and political buzzword that has and is still receiving high media attention. Based on the latter, numerous tiered testing strategies have evolved that should ensure that humans will not run a health risk due to the voluntary or involuntary exposure to endocrine active compounds (EAS). An analysis of the currently available knowledge on EAS mediated endocrine d...

1 Serviço de Endocrinologia, Instituto Português de Oncologia, 1099-023 Lisboa, Portugal 2 Faculdade de Ciências Médicas, Universidade Nova de Lisboa, 1169-056 Lisboa, Portugal 3 Seccion Endocrinologia, Hospital del Salvador, Santiago de Chile, Universidad de Chile, Chile 4Departamento de Endocrinologia, Instituto do Cancer do Estado de São Paulo, Faculdade de Medicina da Universidade de São pa...

Hyperparathyroidism is the commonest presenting feature in multiple endocrine adenomatosis Type I (MEA Type I), the other manifestations may be delayed for many years or appear only in relatives. A family now diagnosed as MEA Type I, who was previously thought, in 1965, to have familial hyperparathyroidism due to chief cell hyperplasia is now described. The importance is stressed of family surv...

During the past 10 years there has been particular interest in the occurrence of a number of endocrine syndromes in association with tumours of organs other than the endocrines. Evidence is increasing to suggest that these result from the formation of hormone-like substances by the tumours. The clinical importance and theoretical implications of these syndromes constitute the justification for ...

Members of four families in which multiple endocrine neoplasia type 2A (MEN-2A) is segregating were typed for seven DNA markers and one red cell enzyme marker on chromosome 13. Close linkage was excluded between the MEN2A locus and each marker locus tested. By means of multipoint analysis and the genetic map of chromosome 13 developed by Leppert et al., MEN2A was excluded from any position betw...

Despite its identification in 1997, the functions of the MEN1 gene-the main gene underlying multiple endocrine neoplasia type 1 syndrome-are not yet fully understood. In addition, unlike the RET-MEN2 causative gene-no hot-spot mutational areas or genotype-phenotype correlations have been identified. More than 1,300 MEN1 gene mutations have been reported and are mostly "private" (family specific...

Multiple endocrine neoplasia 1 (MEN1) is a hereditary syndrome associated with a number of endocrine and nonendocrine tumors. Unfortunately, a diagnosis of MEN1 often is delayed until after the patient has developed an advanced or second MEN1-related tumor. Nurses need to be familiar with hallmark signs of this syndrome to facilitate an early diagnosis and appropriately refer families for genet...